|

Gut Response to Mesothelioma Treatment

ByHolly Zink
Gut Response to Mesothelioma Treatment

An international team of researchers have found that the bacteria in the gut and tumors can affect how well someone responds to treatment for mesothelioma.

The researchers looked at data from 86 patients with malignant mesothelioma. They studied the different types of bacteria in their tumors and how it affected their survival rates.

Conventional Treatment

Malignant mesothelioma is a rare cancer that affects the lining of organs like the lungs and abdominal cavity. It usually has a poor prognosis and limited treatment options. Mesothelioma is caused by exposure to asbestos.

Conventional treatment for malignant mesothelioma typically includes chemotherapy, radiation, and surgery. The exact treatment plan will depend on many factors. Doctors will consider the type of mesothelioma, the condition of the patient, and how much the cancer has spread.

There has been a growing interest in immunotherapy as a treatment option, as well. Immunotherapy is a type of cancer treatment that uses the patient’s immune system to fight their cancer.

Some studies of immunotherapy have shown that the treatment is not always effective. One reason for this could be a patient’s gut bacteria, called the microbiota.

The microbiota is a large collection of good bacteria, fungi, viruses, and other organisms in our bodies. When it’s in balance, it helps keep our body healthy and our immune system strong. But when bad bacteria take over, it can lead to diseases, including cancer.

In the last ten years, studies have found that there are also bacteria in tumors that can affect how they grow and how well they respond to treatment. But there hasn’t been a lot of research on how this affects mesothelioma, a type of cancer.

Gut Bacteria Play a Role

To look at the effect of bacteria on mesothelioma survival, researchers used patient data from the cBioPortal database.

The researchers in this study found 107 types of bacteria that were linked to better or worse survival rates in mesothelioma patients.

They also found that these types of bacteria were linked to how the body uses fats for energy. The researchers think that studying the bacteria in tumors could be helpful in predicting how well someone will do with treatment.

“This foundation will improve understanding of how the microbiome is relevant in [malignant mesothelioma] and may lead to improved patient outcomes,” say the researchers.

Source:

Pentimalli F, Krstic-Demonacos M, Costa C, Mutti L, Bakker EY. Intratumor microbiota as a novel potential prognostic indicator in mesothelioma. Front Immunol. 2023;14:1129513. Published 2023 Mar 14. doi:10.3389/fimmu.2023.1129513. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043377/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…